A 49-year-old man with a history of hypogonadism has an initial total testosterone of 289 ng/dL, a repeat total testosterone of 333 ng/dL, and a free testosterone of 67 pg/mL. Does he qualify for testosterone replacement therapy?

Does This Patient Qualify for Testosterone Replacement Therapy?

Yes, this 49-year-old man qualifies for testosterone replacement therapy based on his consistently low total testosterone levels (289 and 333 ng/dL) and low free testosterone (67 pg/mL), provided he has symptoms of hypogonadism and organic causes have been excluded.

Diagnostic Criteria Met

The Endocrine Society guideline 1 establishes clear biochemical thresholds for hypogonadism:

• Total testosterone < 320 ng/dL (11 nmol/L)
• Free testosterone < 64 pg/mL (220 pmol/L) after age adjustment

Your patient meets both criteria with:

• Two confirmatory total testosterone values of 289 and 333 ng/dL (both below the 320 ng/dL threshold, though the second is borderline)
• Free testosterone of 67 pg/mL (just above the 64 pg/mL cutoff but still in the low range)

The guideline 1 specifically recommends diagnosing hypogonadism in men with symptoms AND signs of testosterone deficiency plus unequivocally and consistently low serum total and/or free testosterone concentrations. The requirement for repeat testing has been satisfied with two measurements.

Critical Next Steps Before Treatment

1. Confirm Symptoms Are Present

The diagnosis requires documented symptoms, not just low numbers. Look specifically for 2:

• Sexual symptoms (most specific): poor morning erections, low sexual desire, erectile dysfunction
• Physical symptoms: inability to perform vigorous activity, reduced muscle mass
• Psychological symptoms: depression, fatigue

Research shows 2 that the three sexual symptoms have the strongest syndromic association with low testosterone. The presence of at least three sexual symptoms combined with total testosterone < 11 nmol/L (317 ng/dL) and free testosterone < 220 pmol/L (64 pg/mL) defines late-onset hypogonadism.

2. Exclude Organic Causes

Before labeling this as functional hypogonadism, rule out 1:

• Primary hypogonadism: Klinefelter syndrome, testicular trauma/radiation, orchitis, cryptorchidism
• Secondary hypogonadism: pituitary/hypothalamic tumors, hyperprolactinemia, hemochromatosis
• Measure: LH, FSH, prolactin at minimum
• Consider pituitary imaging if secondary hypogonadism is suspected

3. Identify Reversible Causes (Functional Hypogonadism)

The guidelines 1, 3 emphasize addressing potentially reversible factors first:

• Obesity (most common reversible cause)
• Medications: opioids, glucocorticoids, anabolic steroid withdrawal
• Comorbidities: diabetes, obstructive sleep apnea, chronic illness
• Lifestyle factors: excessive alcohol, poor sleep

Weight loss and lifestyle modification should be the first-line approach 3 in overweight/obese men before considering testosterone therapy.

Pre-Treatment Safety Assessment

Before initiating therapy, mandatory screening includes 1, 3:

• Prostate evaluation (age > 40): PSA and digital rectal exam to exclude occult prostate cancer
• Hematocrit: contraindicated if > 48-50%
• Cardiovascular history: defer therapy for 3-6 months after major cardiovascular events
• Lower urinary tract symptoms: severe LUTS is a relative contraindication
• Absolute contraindications: untreated prostate or breast cancer, severe heart failure

Treatment Decision Framework

If organic hypogonadism is identified: Testosterone therapy is standard of care and clearly indicated 1.

If functional hypogonadism (no organic cause, related to age/obesity/comorbidities):

1. First approach: Lifestyle modification, weight loss, address reversible factors 3
2. If symptoms persist after 3-6 months: Consider testosterone therapy as shared decision with patient 3, 4
3. Discuss realistic expectations: The American College of Physicians 5 found testosterone provides only small improvements in sexual function and quality of life (effect sizes 0.16-0.23), with little to no benefit for energy, mood, or physical functioning in older men with functional hypogonadism

Important Caveats

The borderline nature of this case warrants caution: The second total testosterone (333 ng/dL) is just above some thresholds but below others. The free testosterone (67 pg/mL) is barely above the 64 pg/mL cutoff. This places the patient in a gray zone where symptom assessment becomes critical 6.

Age consideration: At 49 years old, this patient is younger than most study populations in the functional hypogonadism literature 5, which predominantly enrolled men > 60 years. The evidence base is weaker for men aged 40-50.

Trial of therapy approach: If borderline biochemical values with clear symptoms and no reversible causes, a 3-month trial of testosterone therapy is reasonable 6, with reassessment of symptom improvement to guide continuation.

Long-term safety remains uncertain: Studies 5 typically lasted < 1 year, and trials were not powered to assess cardiovascular events or prostate cancer. Recent evidence 7, 8 is more reassuring about cardiovascular safety, but long-term data in functional hypogonadism remain limited.

Monitoring Requirements

If treatment is initiated 1, 8:

• Follow-up at 3 months, then every 6-12 months
• Monitor: testosterone levels (target mid-normal range 450-600 ng/dL), hematocrit, PSA
• Assess: symptom improvement, adverse effects, adherence
• Discontinue if no symptom improvement after 3-6 months or if adverse effects develop